Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR,...

Clinical Cancer Research 2013 / 03 Vol. 19; Iss. 5

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

Angevin, E., Lopez-Martin, J. A., Lin, C.-C., Gschwend, J. E., Harzstark, A., Castellano, D., Soria, J.-C., Sen, P., Chang, J., Shi, M., Kay, A., Escudier, B.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
19
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-12-2885
Date:
March, 2013
File:
PDF, 566 KB
english, 2013
Conversion to is in progress
Conversion to is failed